DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
PCOS isn\'t monolithic — your dominant phenotype (insulin-resistant vs androgen-excess vs oligo-anovulatory vs lean) determines which GLP-1 fits. Plus metformin combo evidence + fertility restoration timing.
PCOS affects 10-15% of women of reproductive age
GLP-1s have become first-line metabolic therapy for PCOS with BMI ≥30 (AACE 2024 guidance). ~70% of PCOS patients have insulin-resistant phenotype where GLP-1 mechanism directly addresses root cause. But picking the right product depends on which symptoms predominate.
Select your dominant PCOS phenotype
Not sure? Most patients are mixed. Pick your most prominent symptoms — many have all 4 to varying degrees.
The most common PCOS phenotype. Insulin resistance is the underlying driver — hyperinsulinemia stimulates ovarian androgen production AND prevents weight loss. GLP-1s directly address insulin resistance, making this the phenotype with the strongest evidence base.
For this phenotype, metformin + GLP-1 combination is often superior to either alone. Most endocrinologists start metformin first if newly diagnosed, then add GLP-1 if BMI ≥30. Both target the same mechanism via different pathways.
Tirzepatide's dual GIP/GLP-1 mechanism produces greatest improvement in HOMA-IR (insulin resistance index). Emerging PCOS trial data shows 1.5-2.0 point HOMA-IR reduction at 24 weeks.
Same tirzepatide as Mounjaro, FDA-indicated for weight management. Best path if you don't have T2D diagnosis but have severe insulin resistance.
Most-studied GLP-1 for PCOS metabolic improvements. T2D indication unlocks insurance coverage for many insulin-resistant PCOS patients.
FDA-approved for weight management. Standard pathway for insulin-resistant PCOS without T2D diagnosis.
PCOS is not on most insurance approval criteria. To get GLP-1 coverage for PCOS, you typically qualify through BMI ≥30 (weight management indication) or T2D diagnosis (~30% of PCOS patients meet T2D criteria). Discuss insurance pathway with your prescriber.
For insulin-resistant PCOS, metformin + GLP-1 is often superior to either alone. Two different mechanisms targeting the same metabolic dysfunction:
Metformin
Reduces hepatic glucose production. Cheap ($4/month generic). Decades of PCOS data. First-line for newly-diagnosed insulin resistance.
GLP-1
Reduces appetite + improves insulin sensitivity. Weight loss compounds metabolic effects. Best for BMI ≥30 or metformin non-response.
Combined therapy reduces HOMA-IR by 2-3 points typically (vs 1-1.5 either alone). For fertility patients, metformin can continue during pregnancy (category B) — GLP-1 must stop 60-75 days pre-conception.
Initiate Wegovy/Zepbound/Ozempic + metformin combo. Get baseline reproductive labs: AMH, FSH, LH, day-3 estradiol, day-21 progesterone (if cycling), TSH, prolactin.
Typically 7-10% body weight loss. Cycles often begin regularizing month 4-6. Many patients start ovulating spontaneously. Track ovulation with LH strips + temperature.
Discuss with reproductive endocrinologist. Plan washout: stop GLP-1 60-75 days before target conception. Continue metformin (pregnancy category B). Start prenatal vitamins now.
After washout, attempt natural conception. If still anovulatory: clomid/letrozole next step. Severe cases: IVF. Most PCOS patients with successful weight loss conceive within 6 months of natural attempts.
Yes, for the insulin-resistant phenotype (~70% of PCOS patients). Hyperinsulinemia drives ovarian androgen production. GLP-1 reduces insulin → reduces androgens → restores ovulation in 70-80% of obese PCOS patients within 6 months. Less effective for lean PCOS without insulin resistance.
Most endocrinologists start metformin first (cheap, oral, decades of PCOS data). If BMI ≥30 or inadequate response in 3-6 months, add GLP-1. The combination is often superior to either alone — different mechanisms hitting same metabolic pathway.
PCOS is not on most insurance approval criteria. Qualify through: (1) BMI ≥30 for weight management indication (Wegovy, Zepbound), (2) T2D diagnosis if you meet criteria (Ozempic, Mounjaro), or (3) gestational diabetes follow-through after pregnancy. PA letters from endocrinology with PCOS+ documentation help.
For oligo-anovulatory PCOS with BMI ≥30, yes — 70-80% see cycle regularization within 6 months on GLP-1 + 7-10% body weight loss. Patients with severe androgen-driven anovulation may need anti-androgen therapy (spironolactone, OCP) in parallel.
No. All GLP-1s are pregnancy category X. You must stop 60-75 days before attempting conception. Many fertility specialists use GLP-1 as pre-IVF preparation, stopping at cycle start. See our preconception washout timer for exact dates.
Androgenic alopecia from PCOS responds slowly to androgen reduction. Expect 9-12 months for visible improvement after starting GLP-1 + topical minoxidil. Severe cases need anti-androgen therapy (spironolactone 50-100mg) for faster results. Hair products in our hair bundle can accelerate regrowth.
Yes, particularly for fertility-focused patients. Myo-inositol + d-chiro-inositol (40:1 ratio, 4g/day) has independent evidence for ovulation restoration. Many patients use both — different mechanisms. Inositol won't replace GLP-1 for BMI ≥30 but adds value for fertility cohort.